March 15 (Reuters) - Glycyx Pharmaventures :
* Glycyx Pharmaventures and Valeant Pharmaceuticals (NYSE:VRX) agree to binding terms of licensing agreement in the field of oncology
* Deal allows co to commercialize products containing Methylnaltrexone Bromide for oncology indications in countries outside US, Canada
* Glycyx would pay sales-based milestones and royalties to Valeant Source text for Eikon: Further company coverage: VRC.TO